PharmTech Poll Results: OTC Children’s Medications - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

PharmTech Poll Results: OTC Children’s Medications

Untitled Document

PharmTech Poll Results: OTC Children’s Medications

The question:

The US Food and Drug Administration’s Nonprescription Drugs Advisory Committee and Pediatric Advisory Committee recently recommended that over-the-counter cough and cold medications not be given to children under age 6 based on their conclusion that the drugs have not been proven effective according to current research and there is a risk of adverse effects. The committees further recommended that dosing devices be required and standardized using volume measurements for liquid formulations.

Do you agree with the committees that there should be standardized dosing devices for all OTC children’s medications?

Your Answers:

Thanks to all of you who participated in our poll! All respondants agreed that OTC children’s medications should have standardized dosing devices.

One person commented, “These should be sold directly by the pharmacist like the pseudoephedrine formulations so the parents administering the doses understand how to use the dosing device and to make sure the patient is not taking other medication that could impact the dosing.”

To add your comments, click here.

For more on this topic, see:

Wyeth Recalls Cold Medicines, Lawmakers Urge FDA Action

FDA Committees Recommend Ban on Cough and Cold Medications for Young Children

Drug Makers Voluntarily Recall OTC Infant Cough and Cold Medications

FDA to Discuss Pediatric OTC Drugs, Warns Against Codeine Use

To see the results of our previous polls, see the poll archive.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy

Click here